CN1111427C - Extract of cimicifuga rhizome and its preparation process and application - Google Patents
Extract of cimicifuga rhizome and its preparation process and application Download PDFInfo
- Publication number
- CN1111427C CN1111427C CN99100542A CN99100542A CN1111427C CN 1111427 C CN1111427 C CN 1111427C CN 99100542 A CN99100542 A CN 99100542A CN 99100542 A CN99100542 A CN 99100542A CN 1111427 C CN1111427 C CN 1111427C
- Authority
- CN
- China
- Prior art keywords
- extract
- rhizoma cimicifugae
- application
- serum
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a rhizoma cimicifugae extract which is extracted from rhizoma cimicifugae, a preparing method thereof, a pharmaceutical application of the rhizoma cimicifugae extract on increasing the destradiol of content blood serum and reducing the follicle-stimulating hormone content of the blood serum of menopausal females, medicines for promoting bone formation and resisting bone absorption, and a pharmaceutical application for treating female climacteric syndromes.
Description
The present invention relates to a kind of Rhizoma Cimicifugae extract that from the plant Rhizoma Cimicifugae, obtains, and the purposes of preparation technology and this Rhizoma Cimicifugae extract, specifically, be the purposes of this Rhizoma Cimicifugae extract aspect the preparation medicine.
Rhizoma Cimicifugae (Cimicifuga) is Ranunculaceae Rattleroot (Cimicifugeae, s.l.) plant, it comprises RHIIZOMA CIMICIFUGAE FOETIDAE or RHIIZOMA CIMICIFUGAE from Northwest of China (Cimicifuga foetida L), Xingan's Rhizoma Cimicifugae or rhizoma cimicifugae dahuricae [Cimicifuga dahurica (Turcz.) Maxim.] and (Cimicifugananchuanensis).Although up to the present existing many reported in literature to the research of the ingredient of Rhizoma Cimicifugae, but the medical effect of the unification compound that extracts from Rhizoma Cimicifugae is not very desirable, and opposite inventor finds the excellent effect that the Rhizoma Cimicifugae extract that does not have complete separation and purification to become each chemical compound but has each chemical compound and do not had under study for action.Based on above-mentioned research, we have finished the present invention.
An object of the present invention is to provide a kind of Rhizoma Cimicifugae extract that from Rhizoma Cimicifugae, obtains.
Another object of the present invention provides the preparation method of this Rhizoma Cimicifugae extract.
Another purpose of the present invention provides the purposes of this Rhizoma Cimicifugae extract aspect pharmacy, specifically, wherein said medicine has content and the effect that reduces the serum follicle stimulating hormone and the effect of short bone formation and anti-bone resorption that increases the menopausal women serum estradiol, and described medicine can be treated climacteric syndrome or be treated the osteoporosis that climacteric causes.
This Rhizoma Cimicifugae extract obtains by following method:
The ethanol of 60-80% is added in the Rhizoma Cimicifugae sheet, flooded powder, heating in water bath is to 70-80 ℃, reflux, extract, three times each 1-2 hour, is removed medicinal residues, merge extractive liquid,, decompression recycling ethanol is condensed into dry extract, consumption n-hexane extraction dry extract by 1: 2, remove lipid part,, reclaim ethyl acetate by 1: 2 consumption ethyl acetate extraction, obtain extract, Rhizoma Cimicifugae extract promptly of the present invention.
Rhizoma Cimicifugae extract of the present invention preferably carries out purification after said method, purification adopts the conventional method of this area, preferably uses active carbon.
Extract of the present invention is preferred RHIIZOMA CIMICIFUGAE FOETIDAE or RHIIZOMA CIMICIFUGAE from Northwest of China (Cimicifuga foetida L) and preferred 75% the ethanol that uses of using in above-mentioned preparation method.
Discover, Rhizoma Cimicifugae extract of the present invention has content that increases the menopausal women serum estradiol and the effect that reduces the serum follicle stimulating hormone, also have short bone formation and anti-bone resorption simultaneously, find that simultaneously these effects are synergism of wherein ingredient and almost do not have toxicity, separate pure compound composition wherein from this extract after, the above-mentioned effect of pure compound is just not obvious and toxicity is higher.Therefore, this Rhizoma Cimicifugae extract can be used for preparing medicine, the medicine of the osteoporosis that causes in particular for preparation treatment climacteric syndrome and by climacteric syndrome.
Using Rhizoma Cimicifugae extract of the present invention to make active component can become various dosage forms with pharmaceutically acceptable excipient or preparing carriers, and these dosage forms comprise tablet, pill, injection, oral liquid etc.
Below with embodiment or the test example foregoing invention is described better.
Embodiment
Get Rhizoma Cimicifugae sheet 800g, the ethanol of adding 75% flooded powder, heating in water bath is to 70-80 ℃ of reflux, extract, three times, each 1 hour, filtering medicinal residues, merge three times ethanol extract, concentrate recovery ethanol and obtain dry extract 100.0g,, remove lipid part with 2 times n-hexane extraction, the ethyl acetate extraction that reuse is 2 times obtains extract 50.0g, and then activated carbon purification obtains Rhizoma Cimicifugae extract 36.0g to the greatest extent.
Test example 1: toxicological test
The oral cimifugin of mice is measured chmice acute toxicity LD
50(g/kg), calculate, be 0.9978g/kg with the BLISS method.
Test example 2: to extracing the effect of ovary rat
Fertility unpregnancy female rats in age, connect and prick the both sides ovary, performing the operation began vagina way sheet in back 3 days, continuous 5 days, thorough with the proof castration, postoperative 10 days, make intragastrically to every rats gavaged cimifugin 50mg/kg/ days, the blank group gavages normal saline 2ml/ days, and positive controls gavages GENGNIANAN 1.5g/kg/ days, continue 21 days, with body weight, uterus weight, serum E
2(estradiol), serum FSH and serum Lh are observation index.
The result shows, operation group and non-operation group no significant difference aspect body weight, uterus weight; The serum E of operation group
2The serum E of the non-operation group of concentration ratio
2Concentration reduces by 31.2% (P＜0.01), but the serum FSH of operation group increases by 128.5% (P＜0.01) than the serum FSH of non-operation group, shows thus, behind the removal ovary, and serum E
2Level obviously reduces, and FSH obviously increases.
Compare with the blank group, after the administration group is treated with cimifugin and GENGNIANAN, serum E
2Concentration increase by 42.8% and 20.8% respectively, and the content of FSH reduces by 23.2% and 30.2% respectively in the serum, show that thus cimifugin and climacteric Andu are active drugs, and the action effect of the GENGNIANAN of the action effect of the cimifugin of 50mg/kg and 1.5g/kg is suitable.
Test example 3: to the metabolic influence of simulated weightlessness rat sclerotin
Continuous 30 days, gave the oral cimifugin 12mg/kg of rat every day, experimentizes with suspension method (simulation space weightlessness causes the method for bone loss), observes following index:
(i) to the influence of femur biomechanical property
Do the three-point bending fracture test with QTS-25 type flow graph, found that administration group rat femur maximum load, elastic load all significantly increase.
(ii) cortical bone bone amount and bone are constructed influence
Compare with the suspention model control group, the medication group not only obviously increases the cortical bone area on the cross section of femur stage casing, and makes the medullary cavity area that certain minimizing be arranged; Cimifugin can reduce the reduction of bone cross sectional moment of inertia, alleviates the change of suspending the bone geometry that causes in midair.
(iii) bone mineralising
Medication group bone mineral content content and mineralization coefficient raise, and show that Rhizoma Cimicifugae have synchronous increase bone mineral content and organic effect.
In addition, hyperfunction organ culture method carries out experiment in vitro with the inductive bone resorption of parathyroid hormone (PTH), finds that Rhizoma Cimicifugae have tangible anti-bone resorption.
Show that thus Rhizoma Cimicifugae have short bone formation effect and anti-bone resorption, be suitable for use as the medicine of the osteoporosis that climacteric syndrome and climacteric causes.
Claims (3)
1, a kind of Chinese medicine Rhizoma Cimicifugae extract is characterized in that this extract obtains by the following method: the ethanol of 60%-80% is added in the Rhizoma Cimicifugae sheet, flooded powder, heating in water bath is to 70-80 ℃ of reflux, extract, three times, each 1-2 hour, remove the medicinal residues merge extractive liquid,, decompression recycling ethanol is condensed into dry extract, consumption n-hexane extraction dry extract by 1: 2, remove lipid part, extract with ethyl acetate, reclaim ethyl acetate by 1: 2 consumption, obtain extract, i.e. Rhizoma Cimicifugae extract.
2, the purposes of the described extract of a kind of claim 1, it is characterized by this extract increases menopausal women serum estradiol content and the application that reduces in the serum thyroid-stimulating hormone medicine in preparation.
3, the purposes of the described extract of a kind of claim 1 is characterized in that the application of this extract in short bone formation of preparation and anti-bone resorption medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99100542A CN1111427C (en) | 1999-02-08 | 1999-02-08 | Extract of cimicifuga rhizome and its preparation process and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99100542A CN1111427C (en) | 1999-02-08 | 1999-02-08 | Extract of cimicifuga rhizome and its preparation process and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1262938A CN1262938A (en) | 2000-08-16 |
| CN1111427C true CN1111427C (en) | 2003-06-18 |
Family
ID=5270059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99100542A Expired - Lifetime CN1111427C (en) | 1999-02-08 | 1999-02-08 | Extract of cimicifuga rhizome and its preparation process and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1111427C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100460366C (en) * | 2004-08-06 | 2009-02-11 | 崔晓兰 | Cimicifuga rhizome organic acid extraction method and novel uses |
| CN101721505B (en) * | 2009-11-16 | 2011-11-09 | 山东大学威海分校 | Aruncus dioicus extractive with function of antibacterial activity |
-
1999
- 1999-02-08 CN CN99100542A patent/CN1111427C/en not_active Expired - Lifetime
Non-Patent Citations (4)
| Title |
|---|
| 《中国药科大学学他》19(3) 1988-03-01 黄驰等，南川升麻的成分研究 * |
| 《中草药》26(6) 1995-06-01 ***等，中药升麻的化学成分 * |
| 《现代中药药理学》第1版 1997-01-01 王本祥等，天津科学技术出版社 * |
| 《现代中药药理学》第1版 1997-01-01 王本祥等，天津科学技术出版社;《中草药》26(6) 1995-06-01 ***等，中药升麻的化学成分;《中国药科大学学他》19(3) 1988-03-01 黄驰等，南川升麻的成分研究 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1262938A (en) | 2000-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20000049163A (en) | Pharmaceutical and cosmetic antiacne formulations containing plant extracts (krameria triandra or mesua ferrea) | |
| CN1111427C (en) | Extract of cimicifuga rhizome and its preparation process and application | |
| CN103816210A (en) | Pueraria lobata extract and application thereof | |
| AU2010290796B2 (en) | Picrorhiza kurroa extract for prevention, elimination and treatment of infection diseases | |
| CN103274919A (en) | Extraction method of peony overground part | |
| CN104491339A (en) | Seabuckthorn leaf composition for preventing and treating hyperlipidaemia and resisting thrombus and preparation method thereof | |
| CN1114419C (en) | Application of Radix Polygoni Multiflori and its extract in preventing and treating osteoporosis | |
| CN1748725A (en) | Process for preparing semen momordicae seed extract containing triterpene saponin component | |
| CN1323588A (en) | New use of ginseng and ginseng stalk and leaf extractive in preventing and treating osteoposis | |
| CN106109862A (en) | A kind of Rhizoma Paridis extract treating viral influenza | |
| CN100484542C (en) | Chinese medicinal compound recipe for treating osteoporosis and its preparing process | |
| CN115737729B (en) | Ethnic medicine preparation for treating osteoporosis and preparation method thereof | |
| CN107661425B (en) | Pain-relieving ointment and preparation method thereof | |
| CN105410893A (en) | Purely natural health-care food with effect of reducing weight | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN101590206A (en) | Traditional Chinese medicine for treating biliary calculi | |
| CN110051550A (en) | A kind of ar-turmerone inclusion compound and preparation method thereof with sterilization anti-inflammatory effect | |
| CN104490908A (en) | Pharmaceutical composition derived from eucommia ulmoides and use of pharmaceutical composition | |
| CN1274319C (en) | Medical use of phytosterone component in Radix Rhapontici | |
| CN104666350B (en) | Compound zaocys dhumnades oil product | |
| CN1301727C (en) | Externally applied Chinese medicine preparation for treating skin disease and its preparation method | |
| CN1159038C (en) | 'Shuanghuang Yupi' cream for skin healing | |
| CN111000902B (en) | Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof | |
| CN1300604A (en) | Compound forest frog fat medicine for improving immune function and it spreparing process | |
| CN103816274A (en) | Preparation method of anti-osteoporosis composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANDONG LUYE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: SHANDONG GREEN LEAF PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 264003, No. 9, Po Yuen Road, Laishan District, Shandong, Yantai Patentee after: Shandong Luye Pharma Co., Ltd. Address before: 264003, No. 9, Po Yuen Road, Laishan District, Shandong, Yantai Patentee before: Luye Pharmaceutical Co., Ltd., Shandong |
|
| CX01 | Expiry of patent term |
Granted publication date: 20030618 |
|
| CX01 | Expiry of patent term |